The road to drug development and approval is long and expensive. Cumberland Pharmaceutical CEO A.J. Kazimi offers an inside look at the process.
On Friday, the U.S. Food and Drug Administration announced approval of the Amplatzer PFO Occluder device. The PFO Occluder reduces the risk of a stroke in patients who previously had a stroke believed to be caused by a blood clot that passed through a patent foramen ovale (PFO), and then traveled to the brain.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: